Concurrent whole brain radiotherapy and bortezomib for brain metastasis
نویسندگان
چکیده
منابع مشابه
Concurrent whole brain radiotherapy and bortezomib for brain metastasis
BACKGROUND Survival of patients with brain metastasis particularly from historically more radio-resistant malignancies remains dismal. A phase I study of concurrent bortezomib and whole brain radiotherapy was conducted to determine the tolerance and safety of this approach in patients with previously untreated brain metastasis. METHODS A phase I dose escalation study evaluated the safety of b...
متن کاملWhole brain radiotherapy for brain metastasis
Whole brain radiotherapy (WBRT) is a mainstay of treatment in patients with both identifiable brain metastases and prophylaxis for microscopic disease. The use of WBRT has decreased somewhat in recent years due to both advances in radiation technology, allowing for a more localized delivery of radiation, and growing concerns regarding the late toxicity profile associated with WBRT. This has pro...
متن کاملA Bayesian network meta-analysis of whole brain radiotherapy and stereotactic radiotherapy for brain metastasis
This study was conducted to compare the effects of whole brain radiotherapy (WBRT) and stereotactic radiotherapy (SRS) in treatment of brain metastasis.A systematical retrieval in PubMed and Embase databases was performed for relative literatures on the effects of WBRT and SRS in treatment of brain metastasis. A Bayesian network meta-analysis was performed by using the ADDIS software. The effec...
متن کاملGefitinib Alone or with Whole Brain Radiotherapy for Patients with Brain Metastasis from NSCLC
Brain metastases (BM) are found in approximately 20-40% of all patients with non-small-cell lung cancer (NSCLC), especially in adenocarcinoma (Olak 1999; Yawn et al., 2003). The outcomes of BM from NSCLC are very poor with few effective treatment options. The median overall survival time (OS) of patients without treatment is less than 3 months (Nussbaum et al., 1996). Whole brain radiotherapy (...
متن کاملConcurrent Whole Brain Radiotherapy and Short-course Chloroquine in Patients with Brain Metastases: a Pilot Trial.
OBJECTIVE The immune modulatory drug chloroquine (CQ) has been demonstrated to enhance survival following radiotherapy in patients with high-grade glioma in a clinical trial, but the efficacy in patients with brain metastases is unknown. We hypothesized that short-course CQ during whole brain radiotherapy (WBRT) would improve response to local therapy in patients with brain metastases. METHOD...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Radiation Oncology
سال: 2013
ISSN: 1748-717X
DOI: 10.1186/1748-717x-8-204